Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Aeroflot's passenger traffic in May increased by 35.9%

6/9/23 AFLT

Sberbank reported for 5 months of 2023 by RAS

6/9/23 SBER

SPB Clearing became a central counterparty of the Kazakh ITS exchange

6/9/23 SPBE

Surgutneftegas reported for the year 2022 by RAS

6/9/23 SNGS

Depository of SPB Exchange became the depository of the international exchange in Kazakhstan

6/8/23 SPBE

Board of Directors of NCSP recommended that dividends be paid for 2022

6/8/23 NMTP

VK started testing OnePass biometric authorization

6/8/23 VKCO

Board of Directors of Himprom recommended that dividends be paid for 2022

6/8/23 HIMCP

Shareholders of Levenhuk approved dividends for 2022

6/8/23 LVHK

Gazprom postponed the launch of the LNG plant from coal bed methane

6/8/23 GAZP